AAPL 220.794 -3.9943% MSFT 428.035 -0.2319% NVDA 141.6 2.8248% GOOGL 199.57 1.8214% GOOG 201.025 1.759% AMZN 231.2303 2.3415% META 615.98 0.5239% AVGO 241.67 1.7815% TSLA 419.8973 -1.5481% TSM 219.5101 3.7873% LLY 738.3 1.7335% V 323.35 1.167% JPM 263.1299 1.5318% UNH 524.13 2.819% NVO 80.9168 2.8298% WMT 93.0799 1.2398% LVMUY 146.6 3.1813% XOM 111.7187 -0.5353% LVMHF 732.5 3.0167% MA 527.97 0.6232%
AAPL 220.794 -3.9943% MSFT 428.035 -0.2319% NVDA 141.6 2.8248% GOOGL 199.57 1.8214% GOOG 201.025 1.759% AMZN 231.2303 2.3415% META 615.98 0.5239% AVGO 241.67 1.7815% TSLA 419.8973 -1.5481% TSM 219.5101 3.7873% LLY 738.3 1.7335% V 323.35 1.167% JPM 263.1299 1.5318% UNH 524.13 2.819% NVO 80.9168 2.8298% WMT 93.0799 1.2398% LVMUY 146.6 3.1813% XOM 111.7187 -0.5353% LVMHF 732.5 3.0167% MA 527.97 0.6232%

small-cap

Technical Analysis on One NASDAQ- Listed Pharmaceutical Stock- OCUL

Aug 09, 2024 | Team Kalkine
Technical Analysis on One NASDAQ- Listed Pharmaceutical Stock- OCUL

OCUL:NASDAQ
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (US$)

Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye.

 

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Copyright © 2024 Krish Capital Pty Ltd. All rights reserved.